Evolution of Bombesin Conjugates for Targeted PET Imaging of Tumors

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Zhang, Hanwen ^a,b   Abiraj, Keelara ^c   Thorek, Daniel L J ^b   Waser, Beatrice ^d   Smith Jones, Peter M ^b   Honer, Michael ^c   Reubi, Jean Claude ^d   Maecke, Helmut R ^a,e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GAMMA AMINOBUTYRIC ACID DEXTROTRYROSINYLGLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLEUCYLNORLEUCYLAMINE CU 64; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GAMMA AMINOBUTYRIC ACID DEXTROTRYROSINYLGLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLEUCYLNORLEUCYLAMINE CU 67; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GAMMA AMINOBUTYRIC ACID DEXTROTRYROSINYLGLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLEUCYLNORLEUCYLAMINE IN 111; 4 (1,4,8,11 TETRAAZACYCLOTETRADEC 1 YL)METHYL BENZOIC ACID DEXTROTYROSYLGLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLEUCYLMETHIONYLAMINE CU 64; 4 (1,4,8,11 TETRAAZACYCLOTETRADEC 1 YL)METHYL BENZOIC ACID DEXTROTYROSYLGLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLEUCYLMETHIONYLAMINE CU 67; 4 (1,4,8,11 TETRAAZACYCLOTETRADEC 1 YL)METHYL BENZOIC ACID DEXTROTYROSYLGLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLEUCYLNORLEUCYLAMINE CU 64; 4 (1,4,8,11 TETRAAZACYCLOTETRADEC 1 YL)METHYL BENZOIC ACID DEXTROTYROSYLGLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLEUCYLNORLEUCYLAMINE CU 67; 4 (1,4,8,11 TETRAAZACYCLOTETRADEC 1 YL)METHYL BENZOIC ACID GLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLECUYLMETHIONYLAMINE CU 64; 4 (1,4,8,11 TETRAAZACYCLOTETRADEC 1 YL)METHYL BENZOIC ACID GLUTAMINYLTRYPTOPHANYLALANYLVALYLALANYLHISTIDYLLECUYLMETHIONYLAMINE CU 67; BOMBESIN; BOMBESIN RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONJUGATE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG TUMOR LEVEL; FEMALE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; TISSUE DISTRIBUTION; TUMOR DIAGNOSIS; TUMOR XENOGRAFT;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; HUMANS; ISOTOPE LABELING; KINESIS; MICE; MICE, NUDE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84866427436     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044046     Document Type: Article

References (46)

1. Preston SR, Miller GV, Primrose JN, (1996) Bombesin-like peptides and cancer. Crit Rev Oncol Hematol 23: 225-238.
2. Markwalder R, Reubi JC, (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59: 1152-1159.
3. Sun B, Halmos G, Schally AV, Wang X, Martinez M, (2000) Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. The Prostate 42: 295-303.
4. Halmos G, Wittliff JL, Schally AV, (1995) Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 55: 280-287.
5. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, et al. (1985) Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316: 823-826.
6. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L, (2004) High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 31: 803-810.
7. Garrison JC, Rold TL, Sieckman GL, Naz F, Sublett SV, et al. (2008) Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model. Bioconjugate Chem 19: 1803-1812.
8. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, et al. (2006) 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 47: 1144-1152.
9. Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, et al. (2005) Potent Bombesin-like Peptides for GRP-Receptor Targeting of Tumors with 99mTc: A Preclinical Study. J Med Chem 48: 100-110.
10. Schroeder RP, van Weerden WM, Bangma C, Krenning EP, de Jong M, (2009) Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 48: 200-204.
11. Schuhmacher J, Zhang H, Doll J, Maecke HR, Matys R, et al. (2005) GRP Receptor-Targeted PET of a Rat Pancreas Carcinoma Xenograft in Nude Mice with a 68Ga-Labeled Bombesin(6-14) Analog. J Nucl Med 46: 691-699.
12. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, et al. (2004) Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 64: 6707-6715.
13. Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, et al. (2006) 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 47: 492-501.
14. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Maecke HR, Eisenhut M, et al. (2007) 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med 48: 1245-1250.
15. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, et al. (2000) Technetium-99 m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 27: 1694-1699.
16. Van de Wiele C, Phonteyne P, Pauwels P, Goethals I, Van den Broecke R, et al. (2008) Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med 49: 260-264.
17. Baum RP, Prasad V, Frischknecht M, Maecke HR, Reubi JC (2007) Bombesin receptor imaging in various tumors: First results of Ga-68 AMBA PET/CT. Eur J Nucl Med Mol Imaging 34(suppl 2): S193.
18. Abd-Elgaliel WR, Gallazzi F, Garrison JC, Rold TL, Sieckman GL, et al. (2008) Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjugate Chem 19: 2040-2048.
19. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, et al. (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49: 318-326.
20. Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, et al. (2009) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15: 5240-5249.
21. Mansi R, Wang X, Forrer F, Waser B, Cescato R, et al. (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38: 97-107.
22. Fani M, Andre JP, Maecke HR, (2008) 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media & Molecular Imaging 3: 67-77.
23. Shokeen M, Anderson CJ, (2009) Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 42: 832-841.
24. Hoffman TJ, Smith CJ, (2009) True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl Med Bio 36: 579-585.
25. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, et al. (2003) [99 mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30: 247-258.
26. Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, et al. (2011) Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 52: 1970-1978.
27. Maina T, Nock B, Zhang H, Nikolopoulou A, Reubi JC, et al. (2005) Interspecies differences during comparative evaluation of [111In]Z070 and [99mTc]Demobesin 1 in rat or human origin GRP-R-expressing cells and animal models. J Nucl Med 46.
28. Smith-Jones PM, Fridrich R, Kaden TA, Novak-Hofer I, Siebold K, et al. (1991) Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid. Bioconjugate Chem 2: 415-421.
29. Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, et al. (1995) In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med 36: 2315-2325.
30. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, et al. (2010) Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res 70: 3935-3944.
31. De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, et al. (2011) Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med 52: 986-993.
32. Schwarzbach R, Zimmermann K, Blauenstein P, Smith A, Schubiger PA, (1995) Development of a simple and selective separation of 67Cu from irradiated zinc for use in antibody labelling: a comparison of methods. Appl Radiat Isot 46: 329-336.
33. Studer M, Kaden TA, Maecke HR, (1990) Metal complexes with macrocyclic ligands. Part XXXII. Reactivity studies of the pendant carboxylic group in a macrocyclic copper(2+) complex towards amide formation and its use as a protein-labeling agent. Helvetica Chimica Acta 73: 149-153.
34. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M, (2002) Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 8: 1139-1146.
35. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, et al. (2003) MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjugate Chem 14: 756-763.
36. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, et al. (2004) microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 45: 1390-1397.
37. Mantey SA, Weber HC, Sainz E, Akeson M, Ryan RR, et al. (1997) Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem 272: 26062-26071.
38. Pradhan TK, Katsuno T, Taylor JE, Kim SH, Ryan RR, et al. (1998) Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol 343: 275-287.
39. Lin JT, Coy DH, Mantey SA, Jensen RT, (1995) Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors. Eur J Pharmacol 294: 55-69.
40. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, et al. (2007) DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 34: 1198-1208.
41. Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, et al. (1991) CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A 88: 10662-10666.
42. Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, et al. (2007) In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 48: 1327-1337.
43. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, et al. (2007) [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 104: 12462-12467.
44. Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, et al. (2011) PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 52: 1110-1118.
45. Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, et al. (2011) In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 52: 470-477.
46. de Jong M, Maina T, (2010) Of mice and humans: are they the same?- Implications in cancer translational research. J Nucl Med 51: 501-504.